Maria Diaz1, Jasmin Jo2, Mark Smolkin2, Sarah Jane Ratcliffe2, David Schiff2. 1. From the Division of NeuroOncology (D.S.), Department of Neurology (M.D., J.J.), and Department of Public Health Sciences, Division of Biostatistics (M.S., S.J.R.), University of Virginia, Charlottesville. M.D. is currently affiliated with the Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY. J.J. is currently affiliated with the Department of Internal Medicine, Division of Hematology and Oncology, East Carolina University/Vidant Medical Center, Greenville, NC. davidschiff@virginia.edu. 2. From the Division of NeuroOncology (D.S.), Department of Neurology (M.D., J.J.), and Department of Public Health Sciences, Division of Biostatistics (M.S., S.J.R.), University of Virginia, Charlottesville. M.D. is currently affiliated with the Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY. J.J. is currently affiliated with the Department of Internal Medicine, Division of Hematology and Oncology, East Carolina University/Vidant Medical Center, Greenville, NC.
Abstract
OBJECTIVE: To determine the incidence of venous thromboembolism (VTE) in lower-grade gliomas (LGGs, WHO grades II-III) and to stratify the risk of VTE by molecular subtype in gliomas grade II-IV, we performed a retrospective review of a large cohort of patients with glioma. METHODS: We performed a retrospective analysis of a cohort of 635 adult patients with glioma with molecular testing seen at the University of Virginia with a diagnosis of diffuse glioma established from January 2005 to August 2017. Estimates of cumulative incidence of VTE were calculated with death as competing risk; significance was determined using the Fine and Gray model. RESULTS: Of 256 patients with LGG, 81 were isocitrate dehydrogenase (IDH) wild-type; 113 IDH mutant, 1p/19q codeleted; and 62 IDH mutant, 1p/19q intact. With a median follow-up of 17.9 months, the overall cumulative incidence of VTE was 8.2% for grade II (147 patients), 9.2% for grade III (109 patients), and 30.5% for grade IV (334 patients). In grade II-IV patients, absence of an IDH mutation was associated with a threefold increase in VTE risk when compared to IDH-mutant patients (hazard ratio 3.06, 95% confidence interval 2.03-4.64). In patients with glioblastoma, there was no difference in VTE incidence according to O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. CONCLUSION: Patients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated, in the presence of an IDH mutation. MGMT promoter methylation in glioblastoma does not affect the incidence of VTE.
OBJECTIVE: To determine the incidence of venous thromboembolism (VTE) in lower-grade gliomas (LGGs, WHO grades II-III) and to stratify the risk of VTE by molecular subtype in gliomas grade II-IV, we performed a retrospective review of a large cohort of patients with glioma. METHODS: We performed a retrospective analysis of a cohort of 635 adult patients with glioma with molecular testing seen at the University of Virginia with a diagnosis of diffuse glioma established from January 2005 to August 2017. Estimates of cumulative incidence of VTE were calculated with death as competing risk; significance was determined using the Fine and Gray model. RESULTS: Of 256 patients with LGG, 81 were isocitrate dehydrogenase (IDH) wild-type; 113 IDH mutant, 1p/19q codeleted; and 62 IDH mutant, 1p/19q intact. With a median follow-up of 17.9 months, the overall cumulative incidence of VTE was 8.2% for grade II (147 patients), 9.2% for grade III (109 patients), and 30.5% for grade IV (334 patients). In grade II-IV patients, absence of an IDH mutation was associated with a threefold increase in VTE risk when compared to IDH-mutant patients (hazard ratio 3.06, 95% confidence interval 2.03-4.64). In patients with glioblastoma, there was no difference in VTE incidence according to O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. CONCLUSION: Patients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated, in the presence of an IDH mutation. MGMT promoter methylation in glioblastoma does not affect the incidence of VTE.
Authors: A A Brandes; E Scelzi; G Salmistraro; M Ermani; C Carollo; F Berti; P Zampieri; C Baiocchi; M V Fiorentino Journal: Eur J Cancer Date: 1997-09 Impact factor: 9.162
Authors: Michael B Streiff; Xiaobu Ye; Thomas S Kickler; Serena Desideri; Jayesh Jani; Joy Fisher; Stuart A Grossman Journal: J Neurooncol Date: 2015-06-23 Impact factor: 4.130
Authors: Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski Journal: Acta Neuropathol Date: 2016-09-23 Impact factor: 17.088
Authors: Yuan Rong; Vladimir E Belozerov; Carol Tucker-Burden; Gang Chen; Donald L Durden; Jeffrey J Olson; Erwin G Van Meir; Nigel Mackman; Daniel J Brat Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: P Mir Seyed Nazari; J Riedl; M Preusser; F Posch; J Thaler; C Marosi; P Birner; G Ricken; J A Hainfellner; I Pabinger; C Ay Journal: J Thromb Haemost Date: 2018-05-20 Impact factor: 5.824